Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Alexander Egle; Michael Steurer; Thomas Melchardt; Lukas Weiss; Franz Josef Gassner; Nadja Zaborsky; Roland Geisberger; Kemal Catakovic; Tanja Hartmann; Lisa Pleyer; Daniela Voskova; Josef Thaler; Alois Lang; Michael Girschikofsky; Andreas Petzer; Richard Greil

doi:10.1007/s00277-018-3380-z

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Alexander Egle (Erstautor/-in), Michael Steurer, Thomas Melchardt (Co-Autor/-in), Lukas Weiss (Co-Autor/-in), Franz Josef Gassner (Co-Autor/-in), Nadja Zaborsky (Co-Autor/-in), Roland Geisberger (Co-Autor/-in), Kemal Catakovic (Co-Autor/-in), Tanja Hartmann (Co-Autor/-in), Lisa Pleyer (Co-Autor/-in), Daniela Voskova, Josef Thaler, Alois Lang, Michael Girschikofsky, Andreas Petzer, Richard Greil^* (Letztautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

12 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	1825-1839
Fachzeitschrift	ANNALS OF HEMATOLOGY
Jahrgang	97
Ausgabenummer	10
DOIs	https://doi.org/10.1007/s00277-018-3380-z
Publikationsstatus	Veröffentlicht - 2018

Zugriff auf Dokument

10.1007/s00277-018-3380-z

Dieses zitieren

Egle, A., Steurer, M., Melchardt, T., Weiss, L., Gassner, F. J., Zaborsky, N., Geisberger, R., Catakovic, K., Hartmann, T., Pleyer, L., Voskova, D., Thaler, J., Lang, A., Girschikofsky, M., Petzer, A., & Greil, R. (2018). Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. ANNALS OF HEMATOLOGY , 97(10), 1825-1839. https://doi.org/10.1007/s00277-018-3380-z

Egle, Alexander ; Steurer, Michael ; Melchardt, Thomas et al. / Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. in: ANNALS OF HEMATOLOGY 2018 ; Jahrgang 97, Nr. 10. S. 1825-1839.

@article{c79630cc45264550b81806a42826b724,

title = "Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.",

keywords = "INTEGRATIVE GENOMICS VIEWER, MINIMAL RESIDUAL DISEASE, T-CELL SUBSETS, DOUBLE-BLIND, PLUS DEXAMETHASONE, MULTIPLE-MYELOMA, OPEN-LABEL, TRIAL, CYCLOPHOSPHAMIDE, THERAPY",

author = "Alexander Egle and Michael Steurer and Thomas Melchardt and Lukas Weiss and Gassner, \{Franz Josef\} and Nadja Zaborsky and Roland Geisberger and Kemal Catakovic and Tanja Hartmann and Lisa Pleyer and Daniela Voskova and Josef Thaler and Alois Lang and Michael Girschikofsky and Andreas Petzer and Richard Greil",

note = "Egle, Melchardt, Weiss, Pleyer, Greil: Paracelsus Med Univ Salzburg, Oncol Ctr, Hematol \& Med Oncol, Dept Internal Med 3, Salzburg, Austria; Petzer: Lehr-KH! barmh Schwestern Linz",

year = "2018",

doi = "10.1007/s00277-018-3380-z",

language = "English",

volume = "97",

pages = "1825--1839",

journal = "ANNALS OF HEMATOLOGY ",

issn = "0939-5555",

publisher = "Springer Nature",

number = "10",

}

Egle, A, Steurer, M, Melchardt, T , Weiss, L , Gassner, FJ , Zaborsky, N , Geisberger, R, Catakovic, K, Hartmann, T, Pleyer, L, Voskova, D, Thaler, J, Lang, A, Girschikofsky, M, Petzer, A & Greil, R 2018, 'Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.', ANNALS OF HEMATOLOGY , Jg. 97, Nr. 10, S. 1825-1839. https://doi.org/10.1007/s00277-018-3380-z

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. / Egle, Alexander (Erstautor/-in); Steurer, Michael; Melchardt, Thomas (Co-Autor/-in) et al.
in: ANNALS OF HEMATOLOGY , Jahrgang 97, Nr. 10, 2018, S. 1825-1839.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

AU - Egle, Alexander

AU - Steurer, Michael

AU - Melchardt, Thomas

AU - Weiss, Lukas

AU - Gassner, Franz Josef

AU - Zaborsky, Nadja

AU - Geisberger, Roland

AU - Catakovic, Kemal

AU - Hartmann, Tanja

AU - Pleyer, Lisa

AU - Voskova, Daniela

AU - Thaler, Josef

AU - Lang, Alois

AU - Girschikofsky, Michael

AU - Petzer, Andreas

AU - Greil, Richard

N1 - Egle, Melchardt, Weiss, Pleyer, Greil: Paracelsus Med Univ Salzburg, Oncol Ctr, Hematol & Med Oncol, Dept Internal Med 3, Salzburg, Austria; Petzer: Lehr-KH! barmh Schwestern Linz

PY - 2018

Y1 - 2018

KW - INTEGRATIVE GENOMICS VIEWER

KW - MINIMAL RESIDUAL DISEASE

KW - T-CELL SUBSETS

KW - DOUBLE-BLIND

KW - PLUS DEXAMETHASONE

KW - MULTIPLE-MYELOMA

KW - OPEN-LABEL

KW - TRIAL

KW - CYCLOPHOSPHAMIDE

KW - THERAPY

U2 - 10.1007/s00277-018-3380-z

DO - 10.1007/s00277-018-3380-z

M3 - Original Article

C2 - 29862437

SN - 0939-5555

VL - 97

SP - 1825

EP - 1839

JO - ANNALS OF HEMATOLOGY

JF - ANNALS OF HEMATOLOGY

IS - 10

ER -

Egle A, Steurer M, Melchardt T , Weiss L , Gassner FJ , Zaborsky N et al. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. ANNALS OF HEMATOLOGY . 2018;97(10):1825-1839. doi: 10.1007/s00277-018-3380-z